Sarepta Therapeutics

Sarepta Therapeutics shares surge 20% after article suggests drug approval possible
Sarepta Therapeutics shares surge 20% after article suggests drug approval possible
Marketwatch
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
advisory panels
eteplirsen
Flag link:
Here Are Three Ways To Prevent Tragic Battles Between The FDA And Patients
Here Are Three Ways To Prevent Tragic Battles Between The FDA And Patients
Forbes
FDA
patients
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
Flag link:
Biotech stock crashes 50% after disclosing bad news from the FDA
Biotech stock crashes 50% after disclosing bad news from the FDA
Yahoo/Business Insider
Sarepta Therapeutics
eteplirsen
FDA
Duchenne Muscular Dystrophy
Flag link:
FDA panel votes against Sarepta’s drug for Duchenne muscular dystrophy
FDA panel votes against Sarepta’s drug for Duchenne muscular dystrophy
Stat
FDA
Sarepta Therapeutics
eteplirsen
advisory panels
Duchenne Muscular Dystrophy
Flag link:
Sarepta Therapeutics FDA Panel Live Blog
Sarepta Therapeutics FDA Panel Live Blog
TheStreet.com
Sarepta Therapeutics
eteplirsen
FDA
advisory panels
Duchenne Muscular Dystrophy
Flag link:
An Investors' Guide to Sarepta's Eteplirsen FDA Advisory Panel Meeting
An Investors' Guide to Sarepta's Eteplirsen FDA Advisory Panel Meeting
TheStreet.com
Sarepta Therapeutics
eteplirsen
FDA
advisory panels
Duchenne Muscular Dystrophy
Flag link:
Could Desperate Parents' Pleas Sway The FDA To Approve A Drug Even If Evidence It Works Is Lacking?
Could Desperate Parents' Pleas Sway The FDA To Approve A Drug Even If Evidence It Works Is Lacking?
Forbes
FDA
parents
Duchenne Muscular Dystrophy
Sarepta Therapeutics
eteplirsen
Flag link:
Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?
Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?
TheStreet.com
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
Flag link:
FDA Still Negative on Sarepta's DMD Drug, Stock Price Sinks
FDA Still Negative on Sarepta's DMD Drug, Stock Price Sinks
TheStreet.com
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
2 FDA Actions To Watch In April
2 FDA Actions To Watch In April
Seeking Alpha
FDA
Sarepta Therapeutics
eteplirsen
Mycapssa
Chiasma
acromegaly
Duchenne Muscular Dystrophy
Flag link:
Summit develops a unique Duchenne drug for any gene mutation
Summit develops a unique Duchenne drug for any gene mutation
Bizjournals.com
Summit Therapeutics
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Sarepta surges as a group of expert doctors endorses its investigational DMD drug
Sarepta surges as a group of expert doctors endorses its investigational DMD drug
Bidness, ETC
physicians
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
Of These 5 Hated Biotech Stocks, Only 1 Is a Potential Disaster in the Making
Of These 5 Hated Biotech Stocks, Only 1 Is a Potential Disaster in the Making
Motley Fool
INSYS Therapeutics
MannKind
Relypsa
Ziopharma Oncology
Sarepta Therapeutics
Flag link:
​FDA sets new date for hearing on Sarepta’s Duchenne drug
​FDA sets new date for hearing on Sarepta’s Duchenne drug
Bizjournals.com
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
Sarepta shrinks as execs wait for FDA's decision on Duchenne drug
Sarepta shrinks as execs wait for FDA's decision on Duchenne drug
Fierce Biotech
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
Hope for Sarepta Drug Approval Found in Obscure FDA Document
Hope for Sarepta Drug Approval Found in Obscure FDA Document
TheStreet.com
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
Sarepta's Duchenne drug decision delayed: Why it could help win approval
Sarepta's Duchenne drug decision delayed: Why it could help win approval
Bizjournals.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
eteplirsen
Flag link:
Will Sarepta reverse after steep drop?
Will Sarepta reverse after steep drop?
Yahoo/OptionMonster
Sarepta Therapeutics
Flag link:
3 Key FDA Decisions Expected in February
3 Key FDA Decisions Expected in February
24/7 Wall St
FDA
Vertex Pharmaceuticals
Kalydeco
Regulus
RG-101
Sarepta Therapeutics
eteplirsen
Flag link:
Why the FDA shouldn’t bow to parental pressure over Duchenne drug
Why the FDA shouldn’t bow to parental pressure over Duchenne drug
Stat
FDA
Duchenne Muscular Dystrophy
drug approvals
Biomarin
Sarepta Therapeutics
Flag link:

Pages